| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Huang,Qiu-Jin | Chairman | 1.72% | |
| AN JI BIOMEDICAL CO., LTD. | Director | 11.40% | |
| LUMOSA THERAPEUTICS CO., LTD. | Director | 5.73% | |
| Wu,Fu-Gui | Director | 0.00% | |
| Xie,Rong-Sheng | Independent Director | 0.00% | |
| Zhang,Zhi-Han | Independent Director | 0.00% | |
| Zhang,Jia-Zhu | Independent Director | 0.00% |
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 0 | 9,524 | 0 |
| Operating cost | 0 | 2,857 | 0 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 0 | 6,667 | 0 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 0 | 6,667 | 0 |
| Operating expenses | 136,073 | 69,350 | 18,613 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -136,073 | -62,683 | -18,613 |
| Non-operating income and expenses | 17,481 | 27,747 | -3,204 |
| Net profit (loss) before tax | -118,592 | -34,936 | -21,817 |
| Income tax expense (benefits) | 301 | 2,229 | -2,273 |
| Net profit (loss) of ongoing business for the current period | -118,893 | -37,165 | -19,544 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -118,893 | -37,165 | -19,544 |
| Other comprehensive profit (loss), net | - | - | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -118,893 | -37,165 | -19,544 |
| Net profit (loss) attributable to owners of parent company | - | - | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | - | - | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | -2 | 0 | 0 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | - | - | - |
| Net cash inflows (outflows) from investing activities | - | - | - |
| Net cash inflow (outflow) from financing activities | - | - | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | - | - | - |
| Beginning balance of cash and cash equivalents | - | - | - |
| Ending balance of cash and cash equivalents | - | - | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 1,052,304 | 1,153,656 | 1,168,827 |
| Non-current asset | 7,473 | 6,059 | 8,941 |
| Total asset | 1,059,777 | 1,159,715 | 1,177,768 |
| Current liability | 40,597 | 23,255 | 3,165 |
| Non-current liability | 1,613 | 0 | 978 |
| Total liability | 42,210 | 23,255 | 4,143 |
| share capital | 498,000 | 498,000 | 498,000 |
| Equity - secruity token | - | - | - |
| capital reserve | 703,600 | 703,600 | 703,600 |
| retained earning | -184,033 | -65,140 | -27,975 |
| Other equity | - | - | - |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | - | - | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 1,017,567 | 1,136,460 | 1,173,625 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 20 | 22 | 23 |
